A friend of mine from New York recently called and asked about screening for osteoporosis.

Shes 70, jogs five times each week, goes to the gym regularly and dances on weekends. Shes at a normal weight and has never smoked. She eats yogurt, some cheese and every day takes a calcium tablet with vitamin D.

Shes no slouch she exercises right and eats well and she has no family history of osteoporosis. Her mom is 95 and still going strong. When she was 65, her doctor correctly recommended a screening densitometry exam, an X-ray-like test to see how strong bones are.

Hers was slightly low the medical term for this is mild osteopenia. She was unhappy, so shes doing everything she can to stay well.

Yet her bones werent perfect and shes a perfectionist.

Its now five years after the first test, and her doctor wants her to repeat it to see whether shes sliding into the more serious problem of osteoporosis. Shes a stickler when it comes to unnecessary tests especially when it comes to X-rays so she asked me what to do.

Most of you know that osteoporosis is a softening of the bones. Less calcium in your bones means youre more likely to break one. When this occurs in the spine, you have that bent over look. When it occurs in the hip, it means surgery. And for too many, these breaks mean a lifetime of pain and disability.

Now back to my friends question. She had mild osteopenia, which we could relabel as pre-osteoporosis. Osteopenia carries a minimal risk of fractures, but osteoporosis increases your chances tremendously. A recent study from the New England Journal of Medicine addressed this.

Researchers took 5,000 women 65 and older and looked at their bone density. Those with a normal bone density or osteopenia were followed for 15 years, looking to see who progressed to osteoporosis.

Why was this important? Because women with osteoporosis should be offered medications that may help strengthen their bones. And because smart testing, in medicine, means knowing how often to retest.

See the original post:
Dr. Zorba Paster: Screening important for strong bones

Fridays segment of Positive Aging, Dr. Kathy Maupin discussed medical breakthroughs in the treatment of Osteoporosis.

Currently the medical establishment is heralding a new way of delivering Teriparatide, a man-made form of a hormone called parathyroid to treat osteoporosis, via a microchip implanted under the skin see citations below.

St. Louis physician Dr. Kathy Maupin has been implanting all natural bioidentical hormone pellets under the skin for over ten years. In both instances, the application delivers the needed dose of medicine on a daily basis without passing through the digestive system which expectedly impacts the efficacy of the treatment.

The irony is that an implemented microchip of a manufactured hormone is being sanctioned by the medical establishment yet the insertion of all-natural bioidentical hormones under the skin is not.

Be the first to like this post.

Link:
Positive Aging: Osteoporosis

12-03-2012 17:41 Dr.Mark Newkirk is once again on the cutting edge of medicine. Newkirk Family Veterinarians now offer STEM CELL THERAPY for pets. Dr. Mark Newkirk combines traditional medicine and surgery with Holistic Alternatives to access the best of both worlds. As a Veterinarian, Dr. Newkirk has been serving Southern New Jersey for over 25 years. He is extensively trained in medicine and surgery and also is skilled in the care of exotic pets such as reptiles and birds. Dr. Newkirk is also one of only 5 doctors in the country currently undergoing training by the nationally renowned Dr. Martin Goldstein, the author of “The Nature of Animal Healing”, and founder of immuno-augmentative therapy for animals, a true alternative cancer therapy. Dr. Newkirk is a member of American Holistic Veterinary Medical Society, the American Veterinary Medical Association, New Jersey Veterinary Medical Association and the Colorado Veterinary Medical Association. For more information check out Stem Cell Therapy on The Animal Planet’s dogs 101 www.youtube.com

See the original post:
Stem Cell Therapy at Newkirk Family Veterinarians – Hunter’s Story – Video

Join Hallmark Health System for a free osteoporosis screening on Wednesday, April 4, from 11 a.m. to 2 p.m., at Hallmark Health Medical Center, 30 New Crossing Road in Reading.

Screenings offered by Hallmark Health System Rehabilitation Services. Come and speak to healthcare professionals about the risk factors, nutrition and prevention of osteoporosis.

No appointment necessary.

For more information, call 781-213-5140.

Read the rest here:
Hallmark Health offers free April 4 osteoporosis screening

CLEARWATER, FL–(Marketwire -03/12/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK – News) (Pinksheets: BOSM.PK – News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of cardiothoracic surgeon Thomas W. Prendergast, M.D. to its Scientific and Medical Board of Advisors (SAMBA).

Biostem CEO, Dwight Brunoehler stated, “The Company is now positioned for growth and international expansion. Adding a world class team of clinical, laboratory, and regulatory experts for our Scientific and Medical Board of Advisors to guide our pursuits is essential. Dr. Prendergast brings a wealth of experience not only in the scientific aspects of stem cell use in regenerative medicine, but also in forging research and international economic development opportunities.”

Dr. Prendergast is a busy clinical cardiothoracic surgeon, who performs 200-250 open-heart operations and 5 to 15 heart transplants each year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair. He is presently Director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active participant in stem cell research program development and teaching medical students and residents, his other interests include medical research funding and humanitarian development of programs for Disabled American Veterans.

Dr. Prendergast received his undergraduate degrees in biophysics and Psychology, as well as his medical degree, at Pennsylvania State University. His general surgery residency was for five years at the University of Massachusetts Medical School. His cardiothoracic surgery training was at the University of Southern California School of Medicine, including the Los Angeles County Medical Center. Subsequent fellowship training included pediatric cardiac surgery at Children’s Hospital of LA, along with thoracic transplant fellowships at University of Southern California in Los Angeles and at Temple University Hospital in Philadelphia. He spent three years at the University of Kansas establishing thoracic transplant programs until returning to Temple University Hospital as one of their staff heart and lung transplant surgeons. Subsequent to his time at Temple, he joined up with Newark Beth Israel/St. Barnabas Hospitals, where he assumed directorship as the Chief of Cardiac Transplantation and Mechanical Assistance.

Regarding his appointment to the Biostem U.S. Scientific and Medical Board of Advisors, Dr. Prendergast said, “I am looking forward with excitement to working again with Dwight at Biostem. The expansion plan is sound, well paced, and will afford improved quality of life opportunities to many people around the world.”

About Biostem U.S., Corporation

Biostem U.S., Corporation (OTCQB: BOSM.PK – News) (Pinksheets: BOSM.PK – News) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered around providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body’s natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient’s own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company’s goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through www.biostemus.com, or by calling Kerry D’Amato, Marketing Director at 727-446-5000.

More:
Biostem U.S., Corporation Appoints Heart Surgeon, Thomas W. Prendergast, M.D. to Its Scientific and Medical Board of …

Lindsay Porter’s kidneys weighed 16 pounds before her transplant.

STORY HIGHLIGHTS

(CNN) — By the time Lindsay Porter had her kidneys removed two years ago, they were bulging — covered in cysts — and together weighed 16 pounds.

Her abdominal area was so distended, “I looked nine months pregnant, and people regularly asked when I was due,” Porter said.

As she prepared for a transplant to address her polycystic kidney disease, Porter, 47, had mixed feelings — relief to have found a donor, tinged with resignation. She was looking forward to both a new kidney, and a lifetime on immune system-suppressing drugs.

“You get this brand new shiny kidney, and then they give you drugs that eventually destroy it,” said Porter.

But that scenario may eventually change, if results of a new pilot study are replicated in a larger group of patients. The study, published Wednesday in the journal Science Translational Medicine, describes eight kidney transplant patients, including Porter, who received a stem cell therapy that allowed donor and recipient immune cells to coexist in the same body.

The effect, in a handful of those patients, was to trick the recipient’s immune system into recognizing the donated kidney as its own.

When it works, patients become a sort of medical rarity called a chimera.

“Chimerism is a condition wherein two different genetic cell populations are present in the body, and both cell types are tolerated,” said Dr. Anthony Atala, director of the Institute for Regenerative Medicine at Wake Forest Baptist Medical Center, who was not involved in the study, via e-mail.

The rest is here:
Transplant without lifetime of drugs?

The word osteoporosis literally means “porous bones.” It is silent disease which causes loss of bone mass over time leading to bone fractures. Osteoporosis is a common bone disease that affects both men and women, usually as they age.

Facts about osteoporosis:

Osteoporosis is diagnosed with a simple test called a bone density test which is done by a dual energy X-ray absorptiometry (DXA) machine that measures bone mineral density (BMD) in different parts of your body, such as your spine or your hips, to determine if you have osteoporosis. The test is quick and painless.

The results are interpreted as follows: A score between 1 and -1 indicates healthy bones, score between -1 and -2.5, indicates osteopenia, score between -2.5 or lower indicates osteoporosis.

The risk of fractures generally is lower in people with osteopenia when compared with those with osteoporosis.

After reviewing the results of your medical history, physical examination, vitamin D levels and bone density test, you and your healthcare provider can develop a plan to help protect your bones.

The most common first step in treatment of osteoporosis is adequate intake of calcium and vitamin D. Current recommendations from the National Osteoporosis Foundation are as follows: adults under age 50 need a total of 1,000 milligrams of calcium from all sources and 400 to 800 international units (IU) of vitamin D every day. Adults age 50 and older need at total of 1,200 milligrams of calcium from all sources and 800 to 1,000 IU of vitamin D every day.

A number of medications are also used for the prevention and treatment of osteoporosis. Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva) and zoledronic acid (Reclast) are all FDA”‘approved for the prevention and treatment of osteoporosis in postmenopausal women. Alendronate, risedronate, and zoledronic acid are also approved for the treatment of osteoporosis in men and for the prevention and treatment of glucocorticoid-induced osteoporosis in both men and women. These medications help to slow down bone loss and have been shown to decrease the risk of fractures.

You can play your part in reducing your risk of osteoporosis.

Dr. Mazhar Jakhro specializes in family medicine. Board certified, Dr. Jakhro is in practice at Southcoast Primary Care in Dartmouth. He is accepting new patients and can be reached at 508-995-6381.

Read more:
Dr. Mazhar Jakhro: A look at osteoporosis

SAN DIEGO, CA and PORTLAND, OR–(Marketwire -02/28/12)- Medistem Inc. (Pinksheets: MEDS.PK – News) announced today its Annual “Evening with Medistem” Event will take place in Portland, Oregon on March 7th, 2012. The event is being hosted by Vladimir Zaharchook, Vice Chairman at Medistem, Inc., and will feature stem cell luminaries and pioneers working with Medistem including Dr. Amit Patel, Director of Regenerative Medicine at University of Utah and the first person to administer stem cells into patients with heart failure, Dr. Michael Murphy, Vascular Surgeon at Indiana University and Principal Investigator for Medistem’s FDA clinical trial in patients with risk of amputation, and Dr. Alan Lewis, former CEO of the Juvenile Diabetes Research Foundation, advisory board member of Medistem.

In 2007 Medistem discovered an entirely new type of stem cell, the Endometrial Regenerative Cell (ERC). This cell has proven it is a “universal donor” and can be used to treat many more conditions compared to other types of stem cells. The company received FDA clearance to begin clinical trials in September of 2011 for critical limb ischemia, a condition that is associated with amputation. Medistem is also running a Phase II clinical trial for heart failure using the new stem cell. The ERC stem cell does not involve the highly controversial use of fetal tissue, can be produced very economically and administered to the patient in a very simple manner. Medistem is exploring ways to expand clinical trials of its stem cell into other diseases.

“Stem cells and regenerative medicine offer hope in clinical conditions in which hope previously did not exist,” said Dr. Stanley Cohan, Head of Neurology at the St Vincent’s Hospital, the largest center for treatment of multiple sclerosis in the Pacific Northwest, who will be attending the event. “We are honored in the Portland community to have this distinguished team of accomplished researchers and medical doctors convene here and discuss with us possible collaborations.”

“As a long-time member of the Portland academic community, it is exciting to have companies such as Medistem to visit us and share their experiences ‘from the trenches’ of what it takes to push a cellular drug through the FDA,” said Dr. Shoukrat Milipotiv, Associate Scientist in the Division of Reproductive & Developmental Sciences of ONPRC, Oregon Stem Cell Center and Departments of Obstetrics & Gynecology and Molecular & Medical Genetics, and co-director of the ART/ESC core at the Center. He is an internationally recognized researcher in the area of stem cells.

“The Event is an annual celebration to honor our team and collaborators for the successes of the previous year, while at the same time educate the local business and medical community on the latest research on stem cells not just at Medistem but internationally,” said Thomas Ichim, Ph.D Chief Executive Officer of Medistem Inc. “2012 is particularly exciting for us due to approvals for two clinical trials, and the initiation of patient treatments within this context.”

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia and heart failure.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Read more:
Stem Cell Pioneers Converge in Portland to Discuss and Celebrate a Revolutionary New Stem Cell Entering Human Clinical …

Harvard scientists are challenging traditional medical logic that dictates that women are born with a finite amount of eggs.  The scientists said they have discovered the ovaries of young women harbor rare stem cells that are in fact capable of producing new eggs.

If properly harnessed, those stem cells may someday lead to new treatments for women suffering from infertility due to cancer or other diseases – or for those who are simply getting older, according to the researchers.  Lead researcher Jonathan Tilly of Harvard’s Massachusetts General Hospital has co-founded a company, OvaScience Inc., to try to develop the findings into fertility treatments.

The idea that women are born with all the egg cells – called oocytes – they’ll ever have has been called into question by past research, which found egg-producing stem cells in adult mice.

In this latest study, Harvard researchers, in collaboration with Japanese scientists, used donated frozen ovaries from 20 year olds and ‘fished out’ the purported stem cells.  

The researchers inserted a gene into the stem cells, which caused them to glow green.  If the cells produced eggs, those would glow green, too.

The researchers first watched through a microscope as new eggs grew in a lab dish.  They then implanted the human tissue under the skin of mice to provide a nourishing blood supply.  Within two weeks, they observed green-tinged cells forming.

While the work of the Harvard scientists does show potential, there are still questions as to whether the cells are capable of growing into mature, usable eggs.

If so, researchers said, it might be possible one day to use the stem cells in order to grow eggs in lab dishes to help preserve cancer patients’ fertility, which can be harmed by chemotherapy.

Now, I just want to say, while this would be a remarkable discovery – if it pans out – I do have a few concerns. 

I think for specific patients in prime, childbearing ages, who are at risk of losing their fertility for one reason or another, this could be a fruitful discovery for them.

Be that as it may, I am totally against commercializing this technology to the point where women going through menopause look at this as another way of getting pregnant.  For many, this could create incredibly high-risk pregnancies, among other medical problems.

While science is capable of great discovery and innovation – particularly in the field of stem cells – I believe that with reproductive medicine, we should move forward with great caution to minimize any risk to mother and baby.

See the original post here:
Stem cell fertility treatments could be risky for older women

By Carolyn Y. Johnson, Globe Staff

Massachusetts General Hospital researchers reported today they have discovered a rare stem cell in women’s ovaries that they hope one day might be used to make eggs, a claim already generating vigorous debate among scientists familiar with the research.

For decades, it has been thought that women are born with a finite supply of eggs, limiting their reproductive years. Doctors have sought ways of extending the fertility of women, especially as many wait later in life to begin having children.

The research, led by Jonathan Tilly of Mass. General and appearing in the journal Nature Medicine, opens the door to the possibility of taking tissue from a woman’s ovaries, harvesting stem cells from that tissue, and then creating eggs.

But scientists not involved with the Mass. General research said such an approach — if it is even possible — sits far in the future and will require considerably more work. Several scientists said Tilly, who co-founded a company focused on developing novel infertility treatments, had not yet made a convincing case that the stem cells he discovered can yield viable eggs, a critical first step.

Tilly has been a lightning rod in the field of fertility medicine since 2004, when he challenged the orthodoxy that women do not produce new eggs. In a research paper published that year, Tilly laid the foundation for the findings reported yesterday.

“There was a lot of backlash. It wasn’t surprising, given the magnitude of the paradigm shift that was being proposed — this was one of the fundamental beliefs in our field,” Tilly said. “The subsequent eight years have been a long haul.”

In his new study, Tilly extended research by Chinese scientists published in 2009. He developed a technique that allowed scientists to sift out rare stem cells within the ovaries of mice that were tagged and implanted into the ovaries of normal mice. In the mouse ovaries, the stem cells produced eggs, which were removed and fertilized in a laboratory dish. They developed into embryos, although scientists did not use the embryos to produce mice.

Tilly and his team then wanted to know if such cells existed in humans, too.

The research team obtained ovarian tissue removed from young women undergoing sex change operations in Japan and performed the same experiment they’d done with the mouse ovaries. Much to their excitement, they discovered the rare, egg-producing cells in humans.

In later experiments, the human stem cells were used to produce cells that appeared to be eggs. In part because of ethical limitations, researchers were not able to show that the eggs could be used to create human embryos.

Tilly said that he has patented the stem cells and licensed the technology to OvaScience, the startup he co-founded.

Outside researchers described the findings as intriguing and provocative but also raised many questions. Scientists said it was still far from certain that the eggs created in the experiments could be used to produce babies. And they expressed concern that the findings could falsely inflate the hopes of women struggling with infertility.

Dr. David Keefe, chairman of obstetrics and gynecology at New York University Langone Medical Center, said he and other clinicians who see patients would like more than anything to have greater options for women to overcome infertility. But he said the Mass. General researcher had a history of leaping ahead from basic research findings to suggest clinical possibilities.

“Those of us who take care of patients are extremely protective of their hopes,” Keefe said. He noted that a few years ago, he saw half-a-dozen patients who wanted to delay their fertility decisions because of earlier research at Mass. General.

Even if the new findings are immediately replicated in labs around the world, Keefe said, “it’s so far from being clinical that it’s predatory to not be circumspect about it. Humility is an absolute requirement in this field. You’re dealing with people’s hopes and dreams.”

A 2005 study led by Tilly and done in mice suggested bone marrow transplants might offer a way to restore fertility. A year later, a separate group of Harvard researchers showed that this was unlikely to be true. Tilly himself no longer believes this is a way to restore fertility.

“The big difference in that work, now in retrospect, is these non-ovarian sources [of stem cells] don’t appear to do the job,” he said.

Tilly’s work in the past has divided researchers and failed to persuade many in the field that his interpretations are correct.

Teresa Woodruff, a professor of obstetrics and gynecology at the Feinberg School of Medicine at Northwestern University said she had already drawn up a chart of the claims made in the paper, the evidence to support those claims, and the questions they raise. Still, she said, “I do think he’s pushing the envelope in a way that does push all of us to think more broadly.”

Evelyn Telfer, a cell biologist at the University of Edinburgh, who criticized some of Tilly’s earlier work, said she is excited about the new findings. Tilly said that next month, he will fly to Scotland to begin a collaboration with Telfer.

“What he’s saying is we can get these cells,” Telfer said, “and I think it’s pretty convincing.”

The new paper doesn’t offer evidence that such stem cells are active in the ovary, supplying eggs during a woman’s lifetime. But the powerful cells could provide new insights into the important and poorly understood process in biology of egg-formation and allow scientists to look for drugs that might increase the activities of these stem cells, in order to overcome fertility problems.

Skeptics and supporters agreed on one thing: much work lies ahead.

“That’s science,” said Hugh Clarke, a professor in the department of obstetrics and gynecology at McGill University. “Of course, dogma should be challenged, but we shouldn’t assume dogma has been overturned based on a single report.”

Carolyn Y. Johnson can be reached at cjohnson@globe.com. Follow her on Twitter @carolynyjohnson.

Continued here:
Massachusetts General researchers discover stem cell that makes eggs